<DOC>
	<DOC>NCT02967354</DOC>
	<brief_summary>Cross-sectional study to investigate subjects at different stages of type 2 diabetes development with expected stratification of pancreatic islet mass. Non-diabetic individuals were assigned as control. The primary outcome was the [11C]5-hydroxy-tryptophan uptake and retention in the pancreas as a surrogate marker for the endogenous islet mass.</brief_summary>
	<brief_title>[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>5-Hydroxytryptophan</mesh_term>
	<mesh_term>Tryptophan</mesh_term>
	<criteria>Type 2 diabetes fulfilling criteria for the four different study groups, or healthy volunteers Ongoing pregnancy Renal failure (GFR&lt;60 ml/min) Magnetic metal parts in the body Ongoing treatment with selective serotonin receptor inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>